Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03002623 · ClinicalTrials.gov registry record · Phase 2
CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT03002623: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT03002623 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03002623, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland. Researchers believe a new drug called CUDC-907 may be able to help people with thyroid cancer that has spread or has gotten worse. Objective: To see if CUDC-907 will shrink tumors in people with advanced thyroid cancer. Eligibility: People at least 18 years old who have been diagnosed with locally advanced and metastatic thyroid cancer. Design: Participants will be screened with: Medical history Physical exam Blood and urine tests Electrocardiogram (ECG) heart test. Review of their symptoms and how they perform normal activities A scan will be performed. Some will have a computed tomographic scan (CT) that takes pictures of the body using a small amount of radiation. Some will have magnetic resonance imaging (MRI) that uses a magnetic field to take pictures. Bone scan (some participants) Fludeoxyglucose (FDG) positron emission tomography (PET) scan to produce a tumor image. A sample of their tumor from a previous surgery. They may have a biopsy of their tumor if a tumor sample is not available from a previous surgery. Participants will be given CUDC-907 in tablet form. They will take it by mouth once a day for 5 days, then take 2 days off, each week. While taking the study drug, participants will have study visits that repeat the screening tests. After they stop treatment, participants will have 3 follow-up visits over a year. They will repeat some tests. Then participants will be contacted by phone or e-mail every 6 months....
Interventions
- DRUG CUDC-907
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2016-12-22 |
| Est. Completion | 2018-02-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03002623
The ClinicalTrials.gov registry entry for NCT03002623 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CUDC-907 is the first listed.
NCT03002623 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03002623 about?
NCT03002623 is a clinical study titled "CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer". Background: The thyroid is a gland at the base of the throat. Thyroid cancer is a disease that people get when abnormal cells begin to grow in this gland. Researchers believe a new drug called CUDC-907 may be able to help people with thyroid cancer that has spread or has gotten worse. Objective: ...
What is the current status of trial NCT03002623?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-12-22. Estimated completion is 2018-02-12.
What interventions are being tested in trial NCT03002623?
The interventions under investigation include: CUDC-907 (DRUG).
Who is sponsoring clinical trial NCT03002623?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.